2014 DTC National Advertising Awards Finalists
|
|
|
- Stephany Flowers
- 6 years ago
- Views:
Transcription
1 2014 DTC National Advertising Awards Finalists All Gold, Silver, and Bronze winners will be announced at the DTC National Advertising Awards Dinner on April 23. Each therapeutic category winner from Television, Print, Website, and Digital Media will also be entered into an overall Gold, Silver, and Bronze judging for each medium. Finalists listed below in alphabetical order by brand Television Best Television Advertisement Women s Care Bayer Shionogi, Inc. Amgen Mirena Osphena Prolia Best Television Advertisement Mental Health Ostuka America Pharmaceutical Sunovion Abilify Chantix Lunesta Best Television Advertisement Pulmonary GlaxoSmithKline & Boehringer Ingelheim AstraZeneca Advair Spiriva Symbicort
2 Best Television Advertisement Cardiovascular Bristol- Myers Eliquis Squibb/ Boehringer Pradaxa Ingelheim Xarelto Best Television Advertisement Inflammatory Amgen Enbrel Humira Xeljanz Best Television Advertisement Men s Health Androgel Eli Lilly Cialis Viagra Best Television Advertisement Pain Botox Migraine Eli Lilly Cymbalta Lyrica Best Television Advertisement Medical Devices Mylan Epipen Stryker Get Around Knee Lap Band
3 Best Television Advertisement Diabetes Novo Nordisk Levemir LifeScan One Touch Novo Nordisk Victoza Best Television Advertisement Other Juvederm Restasis Genentech Tamiflu Print Women s Care Estring Shionogi Osphena Teva Women s Paragard Health Mental Health Ostuka America Abilify Pharmaceutical Chantix Sunovion Lunesta Pulmonary Merck Dulera & Boehringer Spiriva Ingelheim AstraZeneca Symbicort
4 Cardiovascular AstraZeneca Crestor Boehringer Pradaxa Ingelheim Xarelto Inflammatory Humira Stelara Xeljanz Men s Health Eli Lilly Cialis Dendreon Provenge Viagra Pain Botox Migraine Lyrica Relpax Medical Devices Mylan Epipen Stryker Get Around Knee DePuy Sigma Knee Diabetes Sanofi- Aventis Lantus Novo Nordisk Levemir Novo Nordisk Victoza
5 HIV Bristol- Myers Atripla Squibb and Gilead Prezista Therapeutics Bristol- Myers Reyataz Squibb MS/Alzheimers Acorda Ampyra Therapeautics Novartis Exelon Novartis Gilenya Pharmaceu- ticals Other Restasis Genentech Tamiflu Toviaz Website Women s Care Novartis Oncology Shionogi, Inc. Teva Women s Health Afinitor Osphena Paragard
6 Mental Health Otsuka America Pharmaceutical Noven Therapeutics Lundbeck LLC Pulmonary Merck & Boehringer AstraZeneca Cardiovascular AstraZeneca Boehringer Ingelheim Inflammatory Amgen Shire Men s Health Dendreon Corporation Actavis, Ltd. Abilify Daytrana Onfi Dulera Spiriva Symbicort Crestor Pradaxa Xarelto Enbrel Firazyr Stelara AndroGel Provenge Rapaflo
7 Pain Medical Devices Stryker Given Imaging Diabetes Sanofi- Aventis LifeScan Novo Nordisk HIV Bristol- Myers Squibb Therapeutics Bristol- Myers Squibb MS/Alzheimers Acorda Novartis Biogen Celebrex Lyrica Relpax GetAroundKnee Lap- Band Pill Cam SB Lantus One Touch Victoza Atripla Prezista Reyataz Ampyra Gilenya Tecfidera
8 Other Sanofi U.S. Astellas Ferring Pharmaceuticals Auvi- Q Mybetriq Prepopik Digital Media Women s Care Novartis Oncology Afinitor Estring Teva Women s Paragard Health Mental Health Otsuka America Abilify Pharmaceutical Chantix Sunovion Lunesta Pulmonary Sunovion Alvesco AstraZeneca Symbicort Sepracor, Inc. Xopenex Cardiovascular AstraZeneca Crestor Boehringer Pradaxa Ingelheim Xarelto
9 Inflammatory Amgen Enbrel Humira Xeljanz Men s Health Androgel Eli Lilly Axiron Dendreon Provenge Pain Celebrex Eli Lilly Cymbalta Lyrica Medical Devices Mylan Epipen Stryker GetAroundKnee Medtronic, Inc. Medtronic Diabetes Sanofi- Aventis Lantus Novo Nordisk NovoLog Flexpen Novo Nordisk Victoza HIV Therapeutics Bristol- Myers Squibb Gilead Positively Together Reyataz Stribild
10 MS/Alzheimers Genzyme Aubagio Biogen Tecfidera Novartis Gilenya Pharmaceuticals Other Sanofi U.S. Auvi- Q Teva Nuvigil Pharmaceuticals Biotech, Inc. Stelara Disease Education Disease Education Television Therapeutic Condition Mylan Anaphalaxis GSK Asthma Gilead Hepatitis C Psoraisis Speaks Merck Shingles Disease Education Website Alzheimers Alzheimers Association Association GlaxoSmitKline Asthma.com Crohns & Colitis Escape the Stall Foundation of America My Chronic Migraine My Dry Eyes
11 Disease Education Print Therapeutic Condition Mylan Anaphalaxis Gilead HIV GSK Lupus Migraine RA Drug Launch Drug Launch Therapeutic Condition Ad Agency Novartis Afinitor Metastatic The Oncology breast cancer Cementbloc Sanofi US Auvi- Q Anaphylaxis Publicis Healthcare Communica tions Group Sionogi, Inc. Osphena Painful intercourse due to menopause Publicis Kaplan Thaler Ad Title More Auvi- Q DTC Launch Osphena ed Launch Biogen Tecfidera MS GSW Biogen Tecfidera Drug Launch Xeljanz RA Y&R Body Language
12 CRM CRM Therapeutic Condition Ad Agency Novartis Gilenya MS Saatchi & Saatchi Shionogi, Inc. Osphena Painful intercourse due to menopause Restasis Chronic Dry Eye Wellness Publicis Kaplan Thaler Beacon Healthcare Communica tions RTC Ad Title Gilenya Go Osphena ecrm Your Eyes Novo Nordisk Victoza Type 2 Diabetes VictozaCare Patient Support Xeljanz RA Y&R Xeljanz + You Public Relations Best Public Relations Campaign Therapeutic Condition Genzyme; a Sanofi Company Sanofi Pasteur and March of Dimes Sanofi, U.S. Aubagio Multiple Sclerosis Ad Agency VPR Patient Outreach Ad Title Genzyme MS Ambassadors Unbran- ded Pertussis Biosector 2 The Sounds of Pertussis VPR Patient Outreach Type 1 and 2 Diabetes VPR Patient Outreach AIC Champions Congratulations and best of luck to the finalists. All Gold, Silver, and Bronze winners will be announced at the DTC National Advertising Awards Dinner on April 23. Each therapeutic category winner from Television, Print, Website, and Digital Media will also be entered into an overall Gold, Silver, and Bronze judging for each medium. Be there in person to salute the winners or receive recognition for a job well done.
13 To register for the DTC National Conference, order tickets to the Ad Awards dinner only, or for more details about the event or Advertising Awards, visit or contact the DTC Perspectives office at
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic
Formulary Medical Necessity Program
BENEFIT APPLICATION Formulary Medical Necessity Program DRUG POLICY Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations
US pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health
US pharmaceutical market: trends, issues, forecast Doug Long Vice President Industry Relations IMS Health 2006 Strategic management review The World Pharmaceutical Market All reproduction rights, quotations,
Medication and Dose 10/04/ /05/2016 Total % Change Since 10/2012 ABILIFY 10 MG TABLET $18.76 $ %
Table Comparing NADAC prices for select brand name prescription medications on October 4, 2012 and October 5, 2016 to show how much prices have gone up for these medications. These medications increased
John Ansell President, John Ansell Consultancy Thame, UK
Rutgers University Monday 29 September 2014 Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva 1
HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse
HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs),
SickKids Research Institute: List of Funders
SickKids Research Institute: List of Funders 2009-2010 Agency Funding $ Agency Funding $ 3M Pharmaceuticals 2,901 International Council on Amino Acid Science 80,800 Abbott Diagnostics 6,639 International
ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS
ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS PHM119B September 2016 Anuj Pathak Project Analyst ISBN: 1-62296-345-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA
taking at (Jan. 21, 2016) by Older 2016.pdf).
HSGAC MINORITY STAFF REPORT MANUFACTURED CRISIS How Devastating Drug Increases Are Harming America s Seniors U.S. Senate Homeland Security & Governmental Affairs Committee, Minority Office Page 1 EXECUTIVE
PPHP 2017 Formulary 2017 Step Therapy Criteria
ARISTADA Aristada Prefilled Syringe 1064 MG/3.9ML Intramuscular Aristada Prefilled Syringe 441 MG/1.6ML Intramuscular Aristada Prefilled Syringe 662 MG/2.4ML Intramuscular Aristada Prefilled Syringe 882
Oncology Pipeline Analytics
Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to
DRUG TREND REPORT. WellDyneRx ANNUAL 1 2% 34% WellDyneRx. Diabetes MS Oncology Asthma/COPD HIV. Pain/inflammation. High Blood Choles Attention Disorde
WellDyneRx 34% 1 2% Inflammatory Con Diabetes MS Oncology Asthma/COPD High Blood Pressu HIV Pain/inflammation High Blood Choles Attention Disorde Inflammatory Con Diabetes MS Oncology Asthma/COPD High
ToGA: Trastuzumab with Standard Chemotherapy for HER2-Positive Advanced Gastric Cancer (GC)
ToGA: Trastuzumab with Standard Chemotherapy for HER2-Positive Advanced Gastric Cancer (GC) For more visit ResearchToPractice.com/5MJC CME INFORMATION OVERVIEW OF ACTIVITY Each year, thousands of clinicians
A Clinical Context Report
Stroke Prevention in Atrial Fibrillation An Expert Commentary With Kenneth W. Mahaffey, MD A Clinical Context Report Stroke Prevention in Atrial Fibrillation Expert Commentary Jointly Sponsored by: and
Karan Sharma. Phone: Availability: Fulltime. 4:00 AM to 9:00 PM (GMT) Language groups:
Karan Sharma Phone: +91 7696 060 123 Email: karansharma008@yahoo.co.in Availability: Fulltime 4:00 AM to 9:00 PM (GMT) Language groups: EnglishHindi EnglishPunjabi Skills: Translation Proofreading/Editing
TABLE OF CONTENTS 1 Table of Contents 2 Introduction 3 Key Marketed Products
TABLE OF CONTENTS 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Epidemiology 2.2 Symptoms 2.3 Etiology 2.4 Pathophysiology 2.5 Co-morbidities and Complications 2.6 Classification
PBS Growth. The changing composition of the PBS. PBS Top 10 drugs in transition. Shifting sands for industry as generic volume soars
PBS Growth The changing composition of the PBS PBS Top 10 drugs in transition Shifting sands for industry as generic volume soars The under co-payment market PBS Update 2014-15 Growth in PBS spending was
New Prognostic Markers in Acute Myeloid Leukemia (AML)
New Prognostic Markers in Acute Myeloid Leukemia (AML) For more visit ResearchToPractice.com/5MJCMDSAML CME INFORMATION OVERVIEW OF ACTIVITY Acute myeloid leukemia (AML) and the myelodysplastic syndromes
Russian pharmaceutical market: 2016 vs Anna Ermolaeva AlphaRM General Manager
Russian pharmaceutical market: 2016 vs 2017 Anna Ermolaeva AlphaRM General Manager Russian pharmaceutical market volume 16 ~1,13 (trln, RUB)* & ~5,3 (bln, units) Including Food Supplements (FS), Medical
Disclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.
Disclosures Benjamin M. Scirica, MD, MPH, is employed by the TIMI Study Group, which has received research grants from Abbott, AstraZeneca, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb,
Key ASCO Presentations Issue 4, Effects of Zoledronic Acid on Overall Survival in Newly Diagnosed Multiple Myeloma (MM)
Key ASCO Presentations Issue 4, 2010 Effects of Zoledronic Acid on Overall Survival in Newly Diagnosed Multiple Myeloma (MM) For more visit ResearchToPractice.com/5MJCMT2010 CME INFORMATION OVERVIEW OF
THYROID HORMONE THERAPY TABLE 21 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR FIGURE 4 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 1 SCOPE OF REPORT... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ANALYST S CREDENTIALS...
First-Line Erlotinib with or without Chemotherapy for Never or Light Smokers with Advanced Non-Small Cell Lung Cancer (NSCLC)
Key ASCO Presentations Issue 7, 2010 First-Line Erlotinib with or without Chemotherapy for Never or Light Smokers with Advanced Non-Small Cell Lung Cancer (NSCLC) For more visit ResearchToPractice.com/5MJCMT2010
AUSTRALIA CHINA GERMANY COMPANY BRAND TITLE CATEGORY. Contraceptive Match. Multi-Platform Campaign. Orchard. MSD Australia. Social Video.
COMPANY BRAND TITLE CATEGORY AUSTRALIA Orchard MSD Australia Contraceptive Match Multi-Platform Campaign McCann Health Australia Metamucil Gutsy Social Video SAATCHI and SAATCHI HEALTH SYDNEY Sanofi Pasteur
JOIN IN AN UNPRECEDENTED STATEWIDE MOVEMENT TO CHANGE HEALTHCARE
JOIN IN AN UNPRECEDENTED STATEWIDE MOVEMENT TO CHANGE HEALTHCARE PASBO S STATEWIDE DATA STRATEGY WITH INNOVU PASBO 62 ND ANNUAL CONFERENCE AND EXHIBITS, PITTSBURGH 1 DATA STRATEGY PLATFORM 2 1 WHAT ARE
TECHNICAL APPENDIX: A PERSPECTIVE ON PRESCRIPTION DRUG COPAYMENT COUPONS
TECHNICAL APPENDIX: A PERSPECTIVE ON PRESCRIPTION DRUG COPAYMENT COUPONS METHODS FOR DETERMINING COPAY COUPON STATUS The copay coupon information comes from www.internetdrugcoupons.com (IDC). These data
RVD in Patients with High-Risk, Relapsed/Refractory Multiple Myeloma
RVD in Patients with High-Risk, Relapsed/Refractory Multiple Myeloma For more visit ResearchToPractice.com/5MJC CME INFORMATION OVERVIEW OF ACTIVITY Each year, thousands of clinicians and basic scientists
Phase II Study of Clofarabine for Older Patients with Treatment-Naïve AML
Phase II Study of Clofarabine for Older Patients with Treatment-Naïve AML CME INFORMATION OVERVIEW OF ACTIVITY Acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS) account for approximately
Key ASCO Presentations Issue 2, Ipilimumab Monotherapy for Patients with Melanoma and Brain Metastases
Key ASCO Presentations Issue 2, 2010 Ipilimumab Monotherapy for Patients with Melanoma and Brain Metastases For more visit ResearchToPractice.com/5MJCMT2010 CME INFORMATION OVERVIEW OF ACTIVITY Each year,
CHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Size and Growth of the Market Issues and trends Leading Competitors CHAPTER TWO: INTRODUCTION AND OVERVIEW Definition of Pain Magnitude
Select Inhaled Respiratory Agents
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
Vascular Endothelial Growth Factor Inhibitor Market
May 2017 Report Id : REP-GB-3292 Status : Ongoing Category : Healthcare, Pharmaceuticals & Medical Devices 2015 Future Market Insights, All Rights Reserved About Future Market Insights Future Market Insights
GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES
GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES PHM005C January 2013 Peggy Lehr Project Analyst ISBN: 0-89336-646-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481
COPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global
COPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global Opportunity Analysis and Industry Forecasts, 2015-2022 COPD and
Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial
Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial Christopher Granger, John Alexander, Michael Hanna, Jerry Wang, Puneet Mohan, Jack Lawrence, Elaine Hylek, Jack Ansell,
Key ASH Presentations Issue 2, Lenalidomide in the Management of Chronic Lymphocytic Leukemia (CLL)
Key ASH Presentations Issue 2, 2011 Lenalidomide in the Management of Chronic Lymphocytic Leukemia (CLL) For more visit ResearchToPractice.com/5MJCASH2011 CME INFORMATION OVERVIEW OF ACTIVITY The annual
STEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
JAK AND PI3K SIGNALING PATHWAY MARKETS
JAK AND PI3K SIGNALING PATHWAY MARKETS PHM168A April 2014 Shalini Shahani Dewan Project Analyst ISBN: 1-56965-793-9 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
Critical Pathways in Breast Cancer Treatment
Critical Pathways in Breast Cancer Treatment Faculty Jenny C Chang, MD Paul E Goss, MD, PhD Kathy D Miller, MD Lawrence N Shulman, MD Dennis J Slamon, MD, PhD Andrew Tutt, MB ChB, PhD Editor Neil Love,
Η συμβολή της φαρμακευτικής περίθαλψης στο επίπεδο υγείας. Prof. Nikos Maniadakis
Η συμβολή της φαρμακευτικής περίθαλψης στο επίπεδο υγείας Prof. Nikos Maniadakis Speaker Demographic trends EFPIA, Facts and Figures 2014 Life Expectancy and Drug Spending Higher Drug Spending Correlates
Quality Medical Donations
PQMD members played an active role in relief efforts following devastating floods left by Hurricane s Harvey, Irma, and Maria. PQMD Community of Practice: Connect Convene - Catalyze Are you an engaged
S1207 Trial of Adjuvant Endocrine Therapy with or without Everolimus for High-Risk, Hormone Receptor-Positive, HER2-Negative Breast Cancer
POST-SABCS Issue 1, 2013 S1207 Trial of Adjuvant Endocrine Therapy with or without Everolimus for High-Risk, Hormone Receptor-Positive, HER2-Negative Breast Cancer For more visit ResearchToPractice.com/5MJCSABCS2013
INSIGHT on the Issues
INSIGHT on the Issues AARP Public Policy Institute Rx Watchdog Report: Drug Prices Continue to Climb Despite Lack of Growth in General Inflation Rate AARP s Public Policy Institute finds that average manufacturer
The Global Health Impact Index
The Global Health Impact Index Ranking Explanation Reference Table Drug Abbreviation Drug Name 1. AL 1. Artemether-Lumefantrine 2. AS+AQ 2. Artesunate + Amodiaquine 3. AS+MQ 3. Artesunate + Mefloquine
(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA)
Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corrona Psoriasis Registry AB Gottlieb, B Strober, 2 AW Armstrong, 3 JD Greenberg, 4,5 C Karki, 4
Exhibitor Prospectus. Annual Scientific Assembly October 26 & 27 Westin Buckhead Atlanta, GA. Reserve Space Today!
2017 Exhibitor Prospectus Annual Scientific Assembly October 26 & 27 Westin Buckhead Atlanta, GA Reserve Space Today! The Georgia Academy of Family Physicians is a 70 year old association that represents
DISEASE AWARENESS. Innovative Outreach for Educating Patients and Health Care Providers
REGISTER BY JANUARY 11, 2019 AND SAVE $300! DISEASE AWARENESS CAMPAIGNS Innovative Outreach for Educating Patients and Health Care Providers February 4-5, 2019 Wyndham Philadelphia Historic District Phildelphia
Key ASH Presentations Issue 5, SAVE-ONCO Trial of Thromboprophylactic Treatment with Semuloparin for Venous Thromboembolism
Key ASH Presentations Issue 5, 2012 SAVE-ONCO Trial of Thromboprophylactic Treatment with Semuloparin for Venous Thromboembolism CME INFORMATION OVERVIEW OF ACTIVITY The annual American Society of Hematology
PRACTICAL MANAGEMENT OF NOAC s December 8,
PRACTICAL MANAGEMENT OF NOAC s December 8, 2017 1 Faculty Disclosure Faculty: John Eikelboom MBBS, MSc, FRCPC Jack Hirsh/PHRI Chair in Thrombosis and Atherosclerosis Career Award, Heart and Stroke Foundation
Welcome & Global Genes Mission in Action
Welcome & Global Genes Mission in Action Kym Kilbourne Vice President of Patient Advocacy, Global Genes Proudly supported by: Global Genes Mission To Eliminate the Challenges of Rare Disease We develop
SUNY Binghamton, B.S. Biochemistry, 5/80 SUNY Downstate Medical Center, M.D., 6/84
CURRICULUM VITAE RUSSELL D'AMBRA, M.D. July 2014 North Shore Diabetes & Endocrine Associates 3003 New Hyde Park Road Suite 201 New Hyde Park, New York 11042 516-327-0850 EDUCATION: POST-GRADUATE TRAINING:
BRIC DIABETES DRUGS MARKET
BRIC DIABETES DRUGS MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d M a
International Pharmaceutical Aerosol Consortium on Regulation and Science
International Pharmaceutical Aerosol Consortium on Regulation and Science 1500 K Street NW Washington DC 20005 Telephone +1 202 230 5607 Fax +1 202 842 8465 Email info@ipacrs.org Web www.ipacrs.org Submitted
CHAPTER THREE: INDUSTRY OVERVIEW... 6 HISTORICAL PERSPECTIVE OF THE MENTAL HEALTH INDUSTRY... 6 HISTORICAL PERSPECTIVE OF THE (CONTINUED)...
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR STUDY... 1 SCOPE OF STUDY... 1 METHODOLOGY AND INFORMATION SOURCES... 2 ANALYST CREDENTIALS... 2 RELATED BCC REPORTS... 2 DISCLAIMER...
290O - Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: results from MONALEESA-3
290O - Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: results from MONALEESA-3 Presentation Number: 290O Lecture Time: 11:18-11:33 Speakers: Peter
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Oral Anticoagulants Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Oral Anticoagulant - Bevyxxa (betrixaban), Eliquis (apixaban), Pradaxa (dabigatran),
LETTERS FOR ISSUE ON
S FOR ISSUE ON 27.08.2015 NEW DRUG S. NAME OF APPLICANT DIARY TYPE OF 1. M/S. INTAS PHARMACEUTICALS LIMITED - CT NOC (2) 2. M/S. PFIZER LIMITED - QUERY 3. M/S. MSN LABORATORIES - ADDITIONAL SITE 4. M/S.
Virginia Medicaid April 19, 2018 Meeting
Meeting ABBVIE US LLC ANDROGEL GEL PACKET (TRANSDERM.) ANDROGENIC AGENTS ABBVIE US LLC ANDROGEL GEL PUMP (TRANSDERM) ANDROGENIC AGENTS ABBVIE US LLC CREON (ORAL) PANCREATIC ENZYMES ABBVIE US LLC HUMIRA
Deaths Hospitalizations Company. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Takeda Pharmaceuticals. Janssen Pharmaceuticals
Takeaways: Diabetes Drug Investigation From: BSardi@aol.com Sent: Mon, Dec 22, 2014 at 10:51 am To: Cc: gemcap2@reagan.com martie.whittekin@verizon.net, katjames008@gmail.com clip_image002.jpg (64.5 KB)
PA Start Date Therapeutic Class P&T Review Date 7/1/13 TOP$ (Single Drug Reviews) include:
Maryland Department of Health and Mental Hygiene PDL Prior Authorization Implementation Schedule PA Start Therapeutic Class P&T Review 7/1/13 5/2/13 Antidepressants, Other (ForfivoXL) COPD Agents (Tudorza
2014 ANNUAL CONFERENCE LOUISIANA ASSOCIATION OF HEALTH PLANS SPONSOR EXHIBITOR & GUIDE
2014 ANNUAL CONFERENCE LOUISIANA ASSOCIATION OF HEALTH PLANS SPONSOR EXHIBITOR & GUIDE THE ROOSEVELT NEW ORLEANS DECEMBER 16, 2014 Dear Colleagues, On behalf of the Louisiana Association of Health Plans,
Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath.
Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath. AccuNeb inhalation 0.021% solution: 0.63mg/3mL 3-4 times solution
Decision Making Across the Lifespan
40th Annual Meeting EXHIBIT AND SPONSORSHIP October 14-17, 2018 Fairmont The Queen Elizabeth Montreal, QC, Canada Decision Making Across the Lifespan 2018 OCTOBER 14th - 17th SMDM 390 Amwell Road, Suite
2014 Annual Report. Disseminate the latest and best information impacting the practice of hematology/oncology to members.
Association of Northern California Oncologists 2014 Annual Report The Association of Northern California Oncologists (ANCO) was organized in 1990 to be an advocate for, educate, and inform the practicing
Medicare Part C Medical Coverage Policy
Step Therapy: Part B Medications Origination: December 19, 2018 Review Date: December 19, 2018 Next Review: December 2020 Medicare Part C Medical Coverage Policy DESCRIPTION OF PROCEDURE SERVICE Step Therapy
600 guests , TV broadcast. Collaboration opportunities Contact: David Bell NEWS stories TEAMS
200,000+ BRANDED EMAILS SENT 17 patient representatives 1 TV broadcast 1,276 tweets on awards night 43 EXPERT JUDGES 21 regional NEWS stories 300+ ENTRIES 600 guests 2018 Collaboration opportunities Contact:
BRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH
Insulin Initiation BRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH Disclosures In the past 12 months, I have received speakers honoraria from AstraZeneca, Boehringer Ingelheim,
Global Skin Cancer Diagnosis and Therapeutics Market Research and Forecast
Report Information More information from: https://www.wiseguyreports.com/reports/3186925-global-skin-cancer-diagnosis-and-therapeuticsmarket-research Global Skin Cancer Diagnosis and Therapeutics Market
Quality of medicines in Portugal: a retrospective review of medicine recalls ( ) Ana Teresa Reis Bruna Berardo Rui Loureiro
Quality of medicines in Portugal: a retrospective review of medicine recalls (2005-2015) Ana Teresa Reis Bruna Berardo Rui Loureiro Introduction Human medicines Cosmetics Veterinary medicines Medical devices
Abbott Nutrition 1030 AbbVie 301 AbbVie 907 About the Nurse 207 Academy of Medical-Surgical Nurses 144 Academy of Oncology Nurse & Patient Navigators
Exhibitor Name Booth Number Abbott Nutrition 1030 AbbVie 301 AbbVie 907 About the Nurse 207 Academy of Medical-Surgical Nurses 144 Academy of Oncology Nurse & Patient Navigators 358 Accredo 947 Adako 276
SPECIAL EDITION Issue 2, 2011
SPECIAL EDITION Issue 2, 2011 Benefits of Early ASCT for Newly Diagnosed Multiple Myeloma (MM) and the Incidence of Second Primary Cancer with Lenalidomide Maintenance in the Treatment of MM For more visit
POST-SABCS Issue 4, CALOR Trial of Adjuvant Chemotherapy for Local or Regional Recurrence of Breast Cancer
POST-SABCS Issue 4, 2013 CALOR Trial of Adjuvant Chemotherapy for Local or Regional Recurrence of Breast Cancer For more visit ResearchToPractice.com/5MJCSABCS2013 CME Information OVERVIEW OF ACTIVITY
CHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Total Size and Growth of the Market Issues and Trends Affecting Market Leading Competitors CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
CURRICULUM VITAE Intern in Medicine, Beth Israel Hospital, Harvard Medical School, Boston, MA
Bruce D. Kohrman, M.D. 12305 SW 69 th Place Miami, Florida 33156 Telephone: (305) 903-8678 Fax: (305) 661-1672 CURRICULUM VITAE EDUCATION 1977 - B.S. Stanford University, Stanford, CA 1982 - M.D. Case
This article is a CME/CE certified activity. To earn credit for this activity visit:
Novel Perspectives on Type 2 Diabetes: Traditional and Emerging Therapies and the Potential Role of the Kidneys This article is a CME/CE certified activity. To earn credit for this activity visit: www.medscape.org/lecture/t2dm-therapies
Clinical Trials. Hans-Christoph Diener Senior Professor of Clinical Neuroscienes Medical Faculty University Duisburg-Essen Germany
Clinical Trials Hans-Christoph Diener Senior Professor of Clinical Neuroscienes Medical Faculty University Duisburg-Essen Germany Conflict of Interest Statement German Research Council German Ministry
Changing Treatment Paradigms with Immunotherapy and Targeted Therapy in Advanced Non-Small-Cell Lung Cancer and Head & Neck Cancer
Saturday, October 27, 2018 7:00 AM - 3:45 PM Changing Treatment Paradigms with Immunotherapy and Targeted Therapy in Advanced Non-Small-Cell Lung Cancer and Head & Neck Cancer Program Director John V.
2013 Preferred Drug List An evidence-based pharmacy program that works for you
2013 Preferred Drug List An evidence-based pharmacy program that works for you What is the Moda Health Preferred Drug Program? The Moda Health Preferred Drug Program is a pharmacy program that is designed
Oncology Market Forecast To 2013
Oncology Market Forecast To 2013 How do you uncover the threats and opportunities that your oncology drug will face this year, next year and each year after that? Our new report answers your questions
2013 Preferred Drug List An evidence-based pharmacy program that works for you
2013 Preferred Drug List An evidence-based pharmacy program that works for you What is the Moda Health Preferred Drug Program? The Moda Health Preferred Drug Program is a pharmacy program that is designed
2013 Preferred Drug List An evidence-based pharmacy program that works for you
2013 Preferred Drug List An evidence-based pharmacy program that works for you What is the Moda Health Preferred Drug Program? The Moda Health Preferred Drug Program is a pharmacy program that is designed
Second Opinion An Interactive Case-Based Discussion on the Management of Early and Advanced Breast Cancer
Second Opinion An Interactive Case-Based Discussion on the Management of Early and Advanced Breast Cancer Proceedings from a CME Satellite Symposium at the 30 th Annual San Antonio Breast Cancer Symposium
Current and future market dynamics overview
OVERVIEW Catalyst Summary EXECUTIVE SUMMARY Strategic scoping and focus Datamonitor key findings Related reports MARKET DEFINITION Published diabetes reports Market definition for antidiabetic drugs Forecast
Finding the Positives in Triple- Negative Breast Cancer: A Three- Part Live CME Webcast Series
Finding the Positives in Triple- Negative Breast Cancer: A Three- Part Live CME Webcast Series Seminar I: Wednesday, March 3, 2010, 8:00 PM - 9:00 PM EST Neil Love, MD Editor, Breast Cancer Update Audio
Adherence to therapy. Kamlesh Khunti University of Leicester, UK. William Polonsky University of California San Diego, USA
Adherence to therapy Kamlesh Khunti University of Leicester, UK William Polonsky University of California San Diego, USA 1 Dualities of interest Kamlesh Khunti: Honoraria for speaking, advising or research
American Association for Cardiovascular and Pulmonary Rehabilitation (AACVPR)
Organizations Supporting the Preventive Health Savings Act Academy of Nutrition and Dietetics ACT The App Association Aetna Alliance for Aging Research Allscripts Alzheimer s Association Alzheimer s Impact
Stroke and Headache Headache and Stroke
Stroke and Headache Headache and Stroke Hans-Christoph Diener Senior Professor of Clinical Neurosciences University Duisburg-Essen Tobias Kurth Institute of Public Health Charité Universitätsmedizin Berlin
Patient 1: 31-Year-Old Female. Fingolimod treatment
Cell Counts (10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Lymphocyte Pharmacodynamics and Safety of Use in Patients Previously
Goals and Learning Objectives
Small Airways (SAW) Symposium: Asthma Treatment Issues. New Bronchodilator for Asthma: A Patient Centric Approach for Treating Asthma Stephen P. Peters, MD, PhD, FAAAAI, FACP, FCCP, FCPP Thomas H. Davis
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets March Usha Nagavarapu. Report # PHM113B
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets March 2017 Usha Nagavarapu Report # PHM113B Table of Contents Chapter 1 Introduction... 1 Introduction... 1 Study goals and
Q&A for Group Administrators: Wellmark Announces Strategic Pharmacy Program Changes to Help Control Drug Spend
Learn More Q&A for Group Administrators: Wellmark Announces Strategic Pharmacy Program Changes to Help Control Drug Spend Iowa and South Dakota Pharmacy Benefit Plans This document answers questions regardingupcoming
Presenter Disclosure
Presenter Disclosure Linong Ji.M.D Consulting and lecture fee Eli Lilly, Bristol-Myers Squibb, Novartis, Novo Nordisk, Merck, Bayer, Takeda, Sanofi-Aventis, GlaxoSmithKline, Roche, Johnson & Johnson, boehinger
INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS
INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS PHM162A February 2015 Kim Lawson Project Analyst ISBN: 1-62296-047-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA
Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn
Letter Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, openlabel study J. Rosenstock 1,2,
A study on Metformin (1, 1-Dimethylbiguanidemonohydrochloride) reported adverse events as observed in Eudravigilance database
A study on Metformin (1, 1-Dimethylbiguanidemonohydrochloride) reported adverse events as observed in Eudravigilance database Contract Research Organization / Terzetto Pharma Metrics NIVETHA CHELLAPATHY
JABLONSKI DEBATES PSA TESTING
The JABLONSKI DEBATES PSA TESTING Getting Prostrate for the Prostate The JABLONSKI DEBATES Learning has never been this much fun (just like walking through a field littered with land mines.) The JABLONSKI
SPECIAL EDITION Issue 2, 2011
SPECIAL EDITION Issue 2, 2011 First-Line Therapy for CML-CP with Nilotinib or Dasatinib Compared to Imatinib and the Incidence of Treatment- Emergent BCR-ABL Mutations in Patients Who Received Nilotinib